Linfomas de células B são linfomas que afetam linfócitos B, um tipo de leucócito que produz anticorpos. Os sintomas incluem inchaço nos linfonodos, dor abdominal, cansaço, febre, suores noturnos e perda de peso. Os tumores geralmente se iniciam dentro dos linfonodos, do baço, da medula óssea ou no sangue.
Introdução
O que você precisa saber de cara
Linfoma agressivo de células B, caracterizado por crescimento rápido e disseminação. Pode causar febre, perda de peso, fadiga e dispneia, associado a alterações na medula óssea e ovários. Mutações em genes como MYC e BCL2 são comuns.
Tem tratamento?
Encontrou um erro ou informação desatualizada? Sugira uma correção →
Entender a doença
Do básico ao detalhe, leia no seu ritmo
Preparando trilha educativa...
Sinais e sintomas
O que aparece no corpo e com que frequência cada sintoma acontece
Partes do corpo afetadas
+ 9 sintomas em outras categorias
Características mais comuns
Os sintomas variam de pessoa para pessoa. Abaixo estão as 29 características clínicas mais associadas, ordenadas por frequência.
Linha do tempo da pesquisa
Encontrou um erro ou informação desatualizada? Sugira uma correção →
Genética e causas
O que está alterado no DNA e como passa nas famílias
Genes associados
8 genes identificados com associação a esta condição.
Transcription factor that binds DNA in a non-specific manner, yet also specifically recognizes the core sequence 5'-CAC[GA]TG-3' (PubMed:24940000, PubMed:25956029). Activates the transcription of growth-related genes (PubMed:24940000, PubMed:25956029). Binds to the VEGFA promoter, promoting VEGFA production and subsequent sprouting angiogenesis (PubMed:24940000, PubMed:25956029). Regulator of somatic reprogramming, controls self-renewal of embryonic stem cells (By similarity). Functions with TAF
Nucleus, nucleoplasmNucleus, nucleolusNucleusCytoplasmChromosome
Transcriptional repressor mainly required for germinal center (GC) formation and antibody affinity maturation which has different mechanisms of action specific to the lineage and biological functions. Forms complexes with different corepressors and histone deacetylases to repress the transcriptional expression of different subsets of target genes. Represses its target genes by binding directly to the DNA sequence 5'-TTCCTAGAA-3' (BCL6-binding site) or indirectly by repressing the transcriptional
Nucleus
Suppresses apoptosis in a variety of cell systems including factor-dependent lymphohematopoietic and neural cells (PubMed:1508712, PubMed:8183370). Regulates cell death by controlling the mitochondrial membrane permeability (PubMed:11368354). Appears to function in a feedback loop system with caspases (PubMed:11368354). Inhibits caspase activity either by preventing the release of cytochrome c from the mitochondria and/or by binding to the apoptosis-activating factor (APAF-1) (PubMed:11368354).
Mitochondrion outer membraneNucleus membraneEndoplasmic reticulum membraneCytoplasm
Mediates the nuclear export of cellular proteins (cargos) bearing a leucine-rich nuclear export signal (NES) and of RNAs. In the nucleus, in association with RANBP3, binds cooperatively to the NES on its target protein and to the GTPase RAN in its active GTP-bound form (Ran-GTP). Docking of this complex to the nuclear pore complex (NPC) is mediated through binding to nucleoporins. Upon transit of a nuclear export complex into the cytoplasm, disassembling of the complex and hydrolysis of Ran-GTP
CytoplasmNucleus, nucleoplasmNucleus, Cajal bodyNucleus, nucleolus
Neuronal receptor tyrosine kinase that is essentially and transiently expressed in specific regions of the central and peripheral nervous systems and plays an important role in the genesis and differentiation of the nervous system (PubMed:11121404, PubMed:11387242, PubMed:16317043, PubMed:17274988, PubMed:30061385, PubMed:34646012, PubMed:34819673). Also acts as a key thinness protein involved in the resistance to weight gain: in hypothalamic neurons, controls energy expenditure acting as a nega
Cell membrane
Regulatory component of the cyclin D1-CDK4 (DC) complex that phosphorylates and inhibits members of the retinoblastoma (RB) protein family including RB1 and regulates the cell-cycle during G(1)/S transition (PubMed:1827756, PubMed:1833066, PubMed:19412162, PubMed:33854235, PubMed:8114739, PubMed:8302605). Phosphorylation of RB1 allows dissociation of the transcription factor E2F from the RB/E2F complex and the subsequent transcription of E2F target genes which are responsible for the progression
NucleusCytoplasmNucleus membrane
Serine/threonine protein kinase which activates checkpoint signaling upon double strand breaks (DSBs), apoptosis and genotoxic stresses such as ionizing ultraviolet A light (UVA), thereby acting as a DNA damage sensor (PubMed:10550055, PubMed:10839545, PubMed:10910365, PubMed:12556884, PubMed:14871926, PubMed:15064416, PubMed:15448695, PubMed:15456891, PubMed:15790808, PubMed:15916964, PubMed:17923702, PubMed:21757780, PubMed:24534091, PubMed:35076389, PubMed:9733514). Recognizes the substrate c
NucleusCytoplasmic vesicleCytoplasm, cytoskeleton, microtubule organizing center, centrosomePeroxisome matrix
Ataxia telangiectasia
A rare recessive disorder characterized by progressive cerebellar ataxia, dilation of the blood vessels in the conjunctiva and eyeballs, immunodeficiency, growth retardation and sexual immaturity. Patients have a strong predisposition to cancer; about 30% of patients develop tumors, particularly lymphomas and leukemias. Cells from affected individuals are highly sensitive to damage by ionizing radiation and resistant to inhibition of DNA synthesis following irradiation.
Medicamentos e terapias
Mecanismo: B-lymphocyte antigen CD19 binding agent
Mecanismo: Tubulin inhibitor
Mecanismo: Exportin-1 inhibitor
Mecanismo: B-lymphocyte antigen CD19 binding agent
Mecanismo: T cell surface glycoprotein CD3 binding agent
Mecanismo: T cell surface glycoprotein CD3 binding agent
Mecanismo: B-lymphocyte antigen CD19 binding agent
Mecanismo: B-lymphocyte antigen CD19 binding agent
Mecanismo: FK506-binding protein 1A inhibitor
Variantes genéticas (ClinVar)
9,294 variantes patogênicas registradas no ClinVar.
Vias biológicas (Reactome)
99 vias biológicas associadas aos genes desta condição.
Diagnóstico
Os sinais que médicos procuram e os exames que confirmam
Tratamento e manejo
Remédios, cuidados de apoio e o que precisa acompanhar
Onde tratar no SUS
Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)
🇧🇷 Atendimento SUS — Linfoma não-Hodgkin de células B agressivo
Selecione um estado ou use sua localização para ver resultados.
Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.
Pesquisa ativa
Ensaios clínicos abertos e novidades científicas recentes
Ensaios em destaque
🟢 Recrutando agora
8 pesquisas recrutando participantes. Converse com seu médico sobre a possibilidade de participar.
Outros ensaios clínicos
27 ensaios clínicos encontrados, 12 ativos.
Publicações mais relevantes
Case Report: Glofitamab in the treatment of a patient with central nervous system-involved Burkitt lymphoma.
Burkitt lymphoma (BL) is a rare and highly aggressive B-cell non-Hodgkin lymphoma. While targeted combination chemotherapy can be effective, it is associated with a high rate of relapsed or refractory disease and a pronounced propensity for central nervous system (CNS) involvement. Currently, novel therapies such as chimeric antigen receptor T-cell (CAR-T) therapy have not demonstrated established efficacy in BL. Given the poor prognosis and the challenge of managing relapsed/refractory BL, the use of bispecific antibodies, specifically glofitamab, as employed in this case, has yielded a favorable therapeutic outcome. This is particularly noteworthy in the present case, given the patient's documented CNS infiltration. After the failure of first-line treatment in this case, the combination of glofitamab and a Bruton's tyrosine kinase inhibitor (BTKi) was used for six cycles, which significantly improved the patient's CNS infiltration and achieved a long remission period. This provides an opportunity to try glofitamab in the treatment of CNS lymphoma, and we look forward to its confirmation in more BL patients.
Clinical characteristics, treatment patterns, and survival in mantle cell lymphoma: a real-world cohort.
Mantle cell lymphoma is a rare, typically aggressive B-cell non-Hodgkin lymphoma that often presents at an advanced stage and carries substantial long-term mortality despite therapeutic advances. Multiple clinical, biological, and treatment-related factors may influence survival in these patients. To describe the clinical characteristics, treatment patterns, and overall survival of patients with mantle cell lymphoma at a high-complexity referral center in a middle-income country. This retrospective cohort included adult patients diagnosed and managed at a high-complexity referral center in Colombia between January 2016 and October 2025. Overall survival was the primary outcome. Survival estimates were obtained using Kaplan-Meier curves and compared with log-rank tests. A total of 41 patients were included, with 43.9% aged <65 years. Baseline clinical, laboratory, immunophenotypic, and cytological characteristics were similar across age groups, with most patients presenting with advanced disease, including Ann Arbor stage IV (66.7% vs. 72.3%) and high-risk MIPI classification (88.9% vs. 100%). First-line treatment differed by age, with younger patients more frequently receiving Nordic regimens and older patients receiving R-bendamustine; however, response rates were comparable. Overall survival did not differ significantly by sex, age group, Ann Arbor stage, or LDH levels. In contrast, MIPI category significantly predicted survival (log-rank p=0.017). This real-world cohort describes patients with mantle cell lymphoma presenting predominantly with advanced-stage, high-risk disease. Treatment approaches differed by age, with comparable overall responses across groups. The findings suggest that prognostic indices and functional status assessment may aid outcome evaluation in routine practice.
Long-term follow-up demonstrates the curative potential of dual CD19/CD22 CAR-T-cell therapy alone or combined with autologous stem cell transplantation in TP53-altered relapsed/refractory B-cell non-Hodgkin lymphoma.
The prognostic implications of TP53 alterations in patients with relapsed or refractory (r/r) aggressive B-cell non-Hodgkin lymphoma (B-NHL) treated with chimeric antigen receptor (CAR) T-cell therapy remain inadequately characterized, particularly with respect to long-term outcomes. We report extended follow-up (median: 77.77 months) of 122 patients with r/r B-NHL who received either dual-targeted CD19/CD22 CAR-T-cell therapy alone (cohort A, n = 65) or following sequential autologous stem cell transplantation (ASCT; cohort B, n = 57). TP53 alterations were identified in 59 patients (48.4%). Within both cohorts, overall survival (OS) and progression-free survival (PFS) did not significantly differ between the TP53-altered subgroup and the wild-type subgroup (P >0.05). Notably, compared with CAR-T-cell monotherapy, the sequential ASCT-CAR-T-cell approach (cohort B) was associated with improved 5-year OS (70.2% vs. 40.0%) and PFS (64.9% vs. 35.4%). The 5-year cumulative incidence of nonrelapse mortality was 10.7% overall (9.2% in cohort A vs. 12.3% in cohort B). Secondary malignancies occurred in 2.5% of patients, whereas serious infection-related events beyond 3 months post-infusion were observed in 13.6%, supporting a favorable long-term safety profile. Multivariate analysis identified treatment options and the presence of bulky disease as independent adverse prognostic factors for OS and PFS. These findings suggest that dual-target CD19/CD22 CAR-T-cell therapy, particularly when integrated with ASCT, may mitigate the adverse prognostic influence of TP53 alterations, offering sustained clinical benefit with manageable long-term toxicity in r/r aggressive B-NHL.
Mantle Cell Lymphoma Mimicking Parotid Neoplasm: A Rare Case Report.
Mantle cell lymphoma (MCL) is a rare and aggressive B-cell non-Hodgkin lymphoma, commonly affecting lymph nodes, spleen, bone marrow, and gastrointestinal tract. Salivary gland involvement, especially in the parotid gland, is unusual and often mimics benign conditions, complicating diagnosis. A 58-year-old male presented with a painless, progressively enlarging swelling in the right preauricular region without facial nerve involvement. Imaging revealed a mass within the parotid gland, leading to superficial parotidectomy. Histopathology confirmed mantle cell lymphoma. Immunohistochemical studies showed positivity for CD20, BCL2, CD5, and Cyclin D1; negativity for CD23, CD10, BCL6, and MUM1; and scattered CD3-positive T lymphocytes. The Ki-67 proliferation index was approximately 40%, indicating intermediate proliferative activity. Whole-body PET-CT revealed additional metabolically active lesions suggestive of systemic disease. The patient was started on bendamustine and rituximab chemotherapy. This case highlights that parotid swellings may conceal systemic lymphomas, and misleading cytology can delay diagnosis. Clinicians should consider MCL in atypical parotid lesions to ensure early systemic therapy.
Diagnostic challenges in Burkitt's lymphoma with skull base and paravertebral involvement, and hearing loss: a case report.
Burkitt's lymphoma is a highly aggressive B cell non-Hodgkin lymphoma that typically presents with abdominal tumors or jaw involvement, depending on the variant. Involvement of the skull base or paravertebral regions and associated symptoms such as hearing loss are exceedingly rare in Burkitt's lymphoma. This case highlights the diagnostic challenges when Burkitt's lymphoma presents with such uncommon manifestations in an adult patient. We report a case of a 36-year-old South Asian male individual who presented with generalized body pain, fever, headache, and epigastric discomfort, later developing right-sided facial palsy and hearing loss. Examination revealed mild icterus, lymphadenopathy, and signs of cranial nerve VII involvement. Imaging showed an ill-defined mass at the skull base extending into paravertebral spaces. A comprehensive workup found hematological abnormalities (mild anemia, severe thrombocytopenia) and evidence of hepatic dysfunction. Serologies were notable for positive Epstein-Barr virus IgG. Biopsy of the lesion confirmed Burkitt's lymphoma, demonstrating the characteristic "starry sky" pattern and a near-100% Ki-67 proliferation index. Immunophenotyping was positive for CD20 and leukocyte common antigen, consistent with high-grade B cell lymphoma. Despite initiation of diagnostic procedures, the patient's condition deteriorated rapidly. He opted to return to his home country and unfortunately passed away 2 weeks after diagnosis, before definitive therapy could be administered. This case underscores the importance of recognizing atypical presentations of Burkitt's lymphoma, such as skull base involvement and hearing loss. A high index of suspicion and a multimodal diagnostic approach (imaging and histopathology) were crucial for accurate diagnosis. Early identification of such rare presentations is vital to initiate prompt, appropriate therapy and improve patient outcomes.
Publicações recentes
Unusual Ampullary Presentation of Pediatric Burkitt Lymphoma: Case Report and Literature Review.
Case Report: Glofitamab in the treatment of a patient with central nervous system-involved Burkitt lymphoma.
Clinical characteristics, treatment patterns, and survival in mantle cell lymphoma: a real-world cohort.
Long-term follow-up demonstrates the curative potential of dual CD19/CD22 CAR-T-cell therapy alone or combined with autologous stem cell transplantation in TP53-altered relapsed/refractory B-cell non-Hodgkin lymphoma.
Mantle Cell Lymphoma Mimicking Parotid Neoplasm: A Rare Case Report.
📚 EuropePMC59 artigos no totalmostrando 168
Case Report: Glofitamab in the treatment of a patient with central nervous system-involved Burkitt lymphoma.
Frontiers in oncologyClinical characteristics, treatment patterns, and survival in mantle cell lymphoma: a real-world cohort.
Frontiers in oncologyLong-term follow-up demonstrates the curative potential of dual CD19/CD22 CAR-T-cell therapy alone or combined with autologous stem cell transplantation in TP53-altered relapsed/refractory B-cell non-Hodgkin lymphoma.
Signal transduction and targeted therapyMantle Cell Lymphoma Mimicking Parotid Neoplasm: A Rare Case Report.
Iranian journal of otorhinolaryngologyDiagnostic challenges in Burkitt's lymphoma with skull base and paravertebral involvement, and hearing loss: a case report.
Journal of medical case reportsTrends in Incidence and Survival of Patients With Primary Effusion Lymphoma in the United States: A Population Based Cohort Study.
Hematological oncologyAppendiceal Intussusception Secondary to Mantle Cell Lymphoma: A Report of a Rare Case.
Cureus[Pediatric burkitt lymphoma primarily involving the adenoids: a case report and literature review].
Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology head and neck surgeryMultiple skin tumors in a patient treated with orelabrutinib for mantle-cell lymphoma: Case report.
MedicineTerminal ileum Burkitt's lymphoma related ileocolic intussusception in a five-year-old child: a case report and review of literature.
International journal of surgery case reportsClinical and molecular variations in Burkitt lymphoma.
Translational oncologyMantle cell lymphoma presenting primarily as cutaneous lesions: A case report.
World journal of clinical casesA narrative review on the lactic acidosis and hypoglycemia in burkitt lymphoma: navigating metabolic changes.
Annals of medicine and surgery (2012)Vertebral Involvement in Pediatric Burkitt Lymphoma: A Case Report.
Cureus"B" symptoms and CBV conditioning negatively impact survival in mantle cell lymphoma patients undergoing autologous stem cell transplantation.
Annals of hematologyBurkitt Lymphoma: An Atypical Presentation and Dismal Outcome.
CureusBruton Tyrosine Kinase Inhibitors in Mantle Cell Lymphoma: What Are the Current Options?
European journal of haematologyOvercoming barriers to referral for CAR T-cell therapy in patients with non-Hodgkin aggressive B-cell lymphomas: A Delphi consensus.
CytotherapyComplicated appendicitis as a rare presentation of Burkitt's lymphoma: a case report.
Journal of surgical case reportsSodium 2-Mercaptoethanesulfonate (MESNA), Ifosfamide, Mitoxantrone, and Etoposide (MINE) in Transplant-Ineligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Is the Old Regimen Still Gold?
CureusPrevention and management of infectious diseases in pregnant women with haematological malignancies.
The Lancet. HaematologyUnexplained Bilateral Adrenal Hemorrhage and Adrenal Insufficiency Unveiling Burkitt's Lymphoma.
AACE endocrinology and diabetesSevere Hypercalcemia in Burkitt Lymphoma Following Heart Transplant in an Elderly Male.
CureusNovel PI3Kδ inhibitor exerts antitumor activity in Burkitt lymphoma by inducing ROS-dependent apoptosis.
Medical oncology (Northwood, London, England)[Modern systemic treatment-bispecific antibodies and CAR-T cell therapy : Clinical management, mechanisms of action, outcomes].
Radiologie (Heidelberg, Germany)Primary Solitary Rib Lymphoma on FDG PET/CT.
Clinical nuclear medicineWhen the mouth speaks first: oral Burkitt lymphoma unmasks HIV in a young male.
Oral oncologyLenalidomide in combination with rituximab, dexamethasone, high-dose ARA-C and cisplatinum as salvage therapy in refractory or relapsed aggressive B-cell non-hodgkin-lymphoma - an open-label, multicentre phase I/II study (DSHNHL-R6).
Annals of hematologyCytogenomic and Clinicopathologic Comparison of MYC-Positive and MYC-Negative High-Grade B-Cell Lymphoma With 11q Aberration in the Context of Other Aggressive Lymphomas With MYC Rearrangement.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, IncPlasmablastic lymphoma mimicking primary ovarian, tubal or peritoneal cancer: a case report and literature review.
Discover oncologyLymphoma-on-chip model reveals that lymph node stromal cells promote diffuse large B-cell lymphoma survival and migration.
Materials today. BioLate Adverse Events After Chimeric Antigen Receptor T-Cell Therapy for Patients With Aggressive B-Cell Non-Hodgkin Lymphoma.
JAMA network openExclusion of People Living with HIV in Aggressive B-Cell Non-Hodgkin Lymphoma Studies: A Cross-Sectional Analysis of Clinical Trials from 2014 to 2024.
Cancer investigationHypogammaglobulinemia at Diagnosis is Associated With Inferior Survival and Higher Risk of Infections in Diffuse Large B Cell Lymphoma.
Hematological oncologyIbrutinib With Bendamustine and Rituximab for Treatment of Patients With Relapsed/Refractory Aggressive B-Cell Lymphoma.
Hematological oncologyEffectiveness of fractionated rituximab in preventing tumor lysis syndrome in aggressive B-cell lymphoma: Insights from real-life clinical practice.
Cancer reports (Hoboken, N.J.)Maternal and obstetric outcomes in women with pregnancy-associated haematological malignancies: an observational nationwide cohort study.
The Lancet. HaematologyImpact of critical illness on continuation of anticancer treatment and prognosis of patients with aggressive hematological malignancies.
Annals of intensive careIncidence of Central Nervous System Relapse in Primary Mediastinal Large B-Cell Lymphoma: Implications for Central Nervous System Prophylaxis.
Clinical lymphoma, myeloma & leukemiaAn inherited genetic variant of the CEP72 gene is associated with the development of vincristine-induced peripheral neuropathy in female patients with aggressive B-cell lymphoma.
Annals of hematologyMegaAppendix: a rare case of mantle cell lymphoma in an appendix presented as volvulus.
Journal of surgical case reportsApplications of cell therapy in the treatment of virus-associated cancers.
Nature reviews. Clinical oncologyPrimary CNS Burkitt Lymphoma Presenting as Sudden Bilateral Blindness in a Patient With Underlying Kabuki Syndrome: A Case Report.
CureusInsight into Mantle Cell Lymphoma Pathobiology, Diagnosis, and Treatment Using Network-Based and Drug-Repurposing Approaches.
International journal of molecular sciencesCiwujianoside E inhibits Burkitt lymphoma cell proliferation and invasion by blocking ENO1-plasminogen interaction and TGF-β1 activation.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapieRelapse after glofitamab has a poor prognosis and rates of CD20 loss are high.
British journal of haematologyCombination of acalabrutinib with lenalidomide and rituximab in relapsed/refractory aggressive B-cell non-Hodgkin lymphoma: a single-arm phase II trial.
Nature communicationsUnraveling MCL biology to understand resistance and identify vulnerabilities.
BloodDurable Responses With Mosunetuzumab in Relapsed/Refractory Indolent and Aggressive B-Cell Non-Hodgkin Lymphomas: Extended Follow-Up of a Phase I/II Study.
Journal of clinical oncology : official journal of the American Society of Clinical OncologyChildhood and Adolescent Relapsed/Refractory Aggressive B-Cell Lymphomas With t(8;14) and BCL2 Expression, Burkitt Lymphoma Versus Diffuse Large B-Cell Lymphoma: A Diagnostic Challenge.
Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology SocietyPlasmablastic lymphoma of the sphenoid bone in an immunocompetent patient: A diagnostic challenge.
Indian journal of pathology & microbiologyDistinct FDG PET/CT avidity among newly diagnosed intravascular large B-cell lymphoma patients: a descriptive observational study.
Annals of hematologyEffect and Safety of Orelabrutinib and Lenalidomide Plus R-mini CDOP in Relapsed/Refractory Aggressive B-cell Non-Hodgkin Lymphoma.
Turkish journal of haematology : official journal of Turkish Society of HaematologyIdentifying an optimal fludarabine exposure for improved outcomes after axi-cel therapy for aggressive B-cell non-Hodgkin lymphoma.
Blood advancesUltrasonography-guided core-needle biopsy of lymphadenopathies suspected of lymphoma: Analysis on diagnostic efficacy and safety of 1000 front-line biopsies in a multicenter Italian study.
Hematological oncologyInhibition of a new AXL isoform, AXL3, induces apoptosis of mantle cell lymphoma cells.
BloodLong non-coding RNA as a novel biomarker and therapeutic target in aggressive B-cell non-Hodgkin lymphoma: A systematic review.
Journal of cellular and molecular medicineIncreasing Risk of Lymphoma Over Time in Crohn's Disease but Not in Ulcerative Colitis: A Scandinavian Cohort Study.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological AssociationA novel patient-derived 3D model recapitulates mantle cell lymphoma lymph node signaling, immune profile and in vivo ibrutinib responses.
LeukemiaREGγ promotes mantle cell lymphoma cell apoptosis by downregulating NF-κB signaling.
Translational cancer researchRoles of PI3Kγ and PI3Kδ in mantle cell lymphoma proliferation and migration contributing to efficacy of the PI3Kγ/δ inhibitor duvelisib.
Scientific reportsDon't Put the CART Before the Horse: The Role of Radiation Therapy in Peri-CAR T-cell Therapy for Aggressive B-cell Non-Hodgkin Lymphoma.
International journal of radiation oncology, biology, physicsThe place of allogeneic stem cell transplantation in aggressive B-cell non-Hodgkin lymphoma in the era of CAR-T-cell therapy.
Frontiers in medicineGalunisertib synergistically potentiates the doxorubicin-mediated antitumor effect and kickstarts the immune system against aggressive lymphoma.
International immunopharmacologyCAR T-Cell Therapy for Relapsed/Refractory Aggressive Large B-Cell Lymphoma.
Clinical journal of oncology nursingWhole Transcriptome Sequencing Reveals Cancer-Related, Prognostically Significant Transcripts and Tumor-Infiltrating Immunocytes in Mantle Cell Lymphoma.
CellsStakeholder perception of pharmaceutical value: A multicriteria decision analysis pilot case study for value assessment in the United States.
Journal of managed care & specialty pharmacyPeri-CAR-T practice patterns and survival predictors for all CAR-T patients and post-CAR-T failure in aggressive B-NHL.
Blood advancesPlasmablastic lymphoma: An update.
International journal of laboratory hematologyNon-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL.
NatureImpact of Chronic Kidney Disease and Acute Kidney Injury on Safety and Outcomes of CAR T-Cell Therapy in Lymphoma Patients.
Clinical lymphoma, myeloma & leukemiaOutcomes of patients with diffuse large B-cell and high-grade B-cell lymphomas with synchronous CNS and systemic involvement at diagnosis treated with high-dose methotrexate and R-CHOP: a single-center retrospective study.
Therapeutic advances in hematologyTumor Microenvironment and Immunotherapy-Based Approaches in Mantle Cell Lymphoma.
CancersFlow cytometry can reliably capture gut microbial composition in healthy adults as well as dysbiosis dynamics in patients with aggressive B-cell non-Hodgkin lymphoma.
Gut microbesPhase 2 results of lisocabtagene maraleucel in Japanese patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.
Cancer medicineReal-life Experience With Rituximab-CHOP Every 21 or 14 Days in Primary Mediastinal Large B-cell Lymphoma.
In vivo (Athens, Greece)Impact of CD19 CAR T-cell product type on outcomes in relapsed or refractory aggressive B-NHL.
BloodALK-positive large B-cell lymphomas: A clinicopathologic study.
Indian journal of pathology & microbiologyOutcome of aggressive B-cell lymphoma with TP53 alterations administered with CAR T-cell cocktail alone or in combination with ASCT.
Signal transduction and targeted therapyMidkine inhibitor (iMDK) induces apoptosis of primary effusion lymphoma via G2/M cell cycle arrest.
Leukemia researchCachexia is a risk factor for negative clinical and functional outcomes in patients receiving chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma.
British journal of haematologyAssociation between c-Myc Expression with Clinicopathological Features in T And NK Cell Lymphomas.
Asian Pacific journal of cancer prevention : APJCPLaparoscopic lymph node biopsy for lymphoma with a novel use of indocyanine green fluorescence in a 66-year-old male patient.
International journal of surgery case reportsChildhood aggressive B-cell non-Hodgkin lymphoma in low-middle-income countries.
British journal of haematologyThe Dark Side of Pyroptosis of Diffuse Large B-Cell Lymphoma in B-Cell Non-Hodgkin Lymphoma: Mediating the Specific Inflammatory Microenvironment.
Frontiers in cell and developmental biologyIntegrative genomic and transcriptomic analysis in plasmablastic lymphoma identifies disruption of key regulatory pathways.
Blood advancesSuperior outcomes with paediatric protocols in adolescents and young adults with aggressive B-cell non-Hodgkin lymphoma.
British journal of haematologyClinicopathological and Immunohistochemical Profile of Mantle Cell Lymphoma: An Institutional Experience.
CureusCD19/CD22 Chimeric Antigen Receptor T Cell Cocktail Therapy following Autologous Transplantation in Patients with Relapsed/Refractory Aggressive B Cell Lymphomas.
Transplantation and cellular therapySelection process and causes of non-eligibility for CD19 CAR-T cell therapy in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma in a European center.
Leukemia & lymphomaCucurbitacin B induces apoptosis of primary effusion lymphoma via disruption of cytoskeletal organization.
Phytomedicine : international journal of phytotherapy and phytopharmacologyChimeric Antigen Receptor T Cells for B-Cell Lymphoma.
Cancer journal (Sudbury, Mass.)C(h)AR-ting a new course in incurable lymphomas: CAR T cells for mantle cell and follicular lymphomas.
Blood advancesGenomic characterization of HIV-associated plasmablastic lymphoma identifies pervasive mutations in the JAK-STAT pathway.
Blood cancer discoveryThe treatment of Burkitt lymphoma in adults.
BloodPhase I/II study of bendamustine in combination with ofatumumab, carboplatin, etoposide (BOCE) for relapsed or refractory aggressive B-cell non-Hodgkin lymphoma.
Leukemia & lymphomaEfficacy and safety of lipegfilgrastim versus pegfilgrastim in elderly patients with aggressive B cell non-Hodgkin lymphoma (B-NHL): results of the randomized, open-label, non-inferiority AVOID neutropenia study.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in CancerAn HIV Associated Plasmablastic Lymphoma With Spontaneous Tumor Lysis Syndrome.
CureusEndemic Burkitt lymphoma: a complication of asymptomatic malaria in sub-Saharan Africa based on published literature and primary data from Uganda, Tanzania, and Kenya.
Malaria journalAxicabtagene Ciloleucel in the Non-Trial Setting: Outcomes and Correlates of Response, Resistance, and Toxicity.
Journal of clinical oncology : official journal of the American Society of Clinical OncologyChimeric Antigen Receptors for the Tumour Microenvironment.
Advances in experimental medicine and biologyOpen-Label, phase 2 study of blinatumomab as second salvage therapy in adults with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.
Leukemia & lymphomaNovel agents for mantle cell lymphoma: molecular rational and clinical data.
Expert opinion on investigational drugsExploring the Dilemma of Allogeneic Hematopoietic Cell Transplantation after Chimeric Antigen Receptor T Cell Therapy: To Transplant or Not?
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationAggressive B-Cell Lymphoma Involving the Appendix and Bilateral Ovaries in an 11-Year-Old Girl.
Journal of pediatric and adolescent gynecologyTreatment of relapsed/refractory paediatric aggressive B-cell non-Hodgkin lymphoma.
British journal of haematologyMicroRNA-21 and microRNA-155 promote the progression of Burkitt's lymphoma by the PI3K/AKT signaling pathway.
International journal of clinical and experimental pathologyAntiproliferative and proapoptotic effects of Inula viscosa extract on Burkitt lymphoma cell line.
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and MedicinePrimary Dural Diffuse Large B-cell Lymphoma: A Comprehensive Review of Survival and Treatment Outcomes.
Clinical lymphoma, myeloma & leukemiaPixantrone plus rituximab versus gemcitabine plus rituximab in patients with relapsed aggressive B-cell non-Hodgkin lymphoma not eligible for stem cell transplantation: a phase 3, randomized, multicentre trial (PIX306).
British journal of haematologyFour versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial.
Lancet (London, England)Outcomes in patients with aggressive B-cell non-Hodgkin lymphoma after intensive frontline treatment failure.
CancerBurkitt lymphoma of the maxilla in a HIV positive male - Presentation and review of diagnostic laboratory tests.
Oral and maxillofacial surgery casesUse of Chimeric Antigen Receptor T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B Cell Non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationUpfront autologous hematopoietic stem cell transplantation consolidation for patients with aggressive B-cell lymphomas in first remission in the rituximab era: A systematic review and meta-analysis.
CancerBurkitt lymphoma presenting with fever of unknown origin and isolated hypoglossal nerve palsy.
Journal of the American Association of Nurse PractitionersChimeric antigen receptor T-cell therapy for the treatment of aggressive B-cell non-Hodgkin lymphomas: efficacy, toxicity, and comparative chimeric antigen receptor products.
Expert opinion on biological therapyCD19 CAR T cells following autologous transplantation in poor-risk relapsed and refractory B-cell non-Hodgkin lymphoma.
BloodIntussusception in children: lessons learned from intestinal lymphoma as a rare lead-point.
Pediatric surgery internationalRituximab and reduced-intensity chemotherapy in children and adolescents with mature B-cell lymphoma: interim results for 231 patients enrolled in the second Russian-Belorussian multicentre study B-NHL-2010M.
British journal of haematologyReview of Bruton tyrosine kinase inhibitors for the treatment of relapsed or refractory mantle cell lymphoma.
Current oncology (Toronto, Ont.)Bilateral mantle cell lymphoma of the ciliary body that responded to a combined local radiotherapy and chemotherapy regimen: a case report.
BMC cancerChimeric Antigen Receptor-Engineered T Cell Therapy in Lymphoma.
Current oncology reportsManagement of adults with Burkitt lymphoma.
Clinical advances in hematology & oncology : H&OThe response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells.
BloodTreatment of aggressive B-cell non-Hodgkin lymphoma beyond frontline therapy in patients not eligible for stem cell transplantation: a structured review.
Leukemia & lymphomaRecent advances and future directions in mantle cell lymphoma research: report of the 2018 mantle cell lymphoma consortium workshop.
Leukemia & lymphomaCD19 Chimeric Antigen Receptor Therapy for Refractory Aggressive B-Cell Lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical OncologyHigh-grade Burkitt Lymphoma Presenting as a Buttock Mass and Foot Drop.
CureusThe acceleration of CAR-T therapy in non-Hodgkin lymphoma.
Hematological oncologyThe rationale for combination therapy in patients with aggressive B-cell non-Hodgkin lymphoma: ten questions.
Future oncology (London, England)Phase I Study of the Combination of Bendamustine, Rituximab, and Pixantrone in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma.
Clinical lymphoma, myeloma & leukemiaAssessment of CD52 expression in "double-hit" and "double-expressor" lymphomas: Implications for clinical trial eligibility.
PloS oneThe Role of Macrophage/B-Cell Interactions in the Pathophysiology of B-Cell Lymphomas.
Frontiers in oncologyPre-clinical activity of targeting the PI3K/Akt/mTOR pathway in Burkitt lymphoma.
OncotargetImpact of salvage treatment modalities in patients with positive FDG-PET/CT after R-CHOP chemotherapy for aggressive B-cell non-Hodgkin lymphoma.
Journal of medical imaging and radiation oncologyDoes maintenance therapy have a role in mantle cell lymphoma treatment?
Expert review of hematologyLow rate of spleen involvement in sporadic Burkitt lymphoma at staging on PET-CT.
Abdominal radiology (New York)Burkitt's lymphoma with placental invasion diagnosed at cesarean delivery: a case report.
Journal of medical case reportsTriptolide induces mitochondria-mediated apoptosis of Burkitt's lymphoma cell via deacetylation of GSK-3β by increased SIRT3 expression.
Toxicology and applied pharmacologyConsolidation radiotherapy for advanced-stage aggressive B-cell non-Hodgkin lymphoma: A systematic review and meta-analysis.
EXCLI journalNodular lymphocyte-predominant Hodgkin lymphoma: a unique disease deserving unique management.
Hematology. American Society of Hematology. Education ProgramOutcomes after Allogeneic Stem Cell Transplantation in Patients with Double-Hit and Double-Expressor Lymphoma.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationPegylated GCSF Can Be Used With First-Line da-EPOCH-R Without Compromising Dose Intensity, Safety, or Efficacy.
Clinical lymphoma, myeloma & leukemiaRandomized, phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.
British journal of haematologyA randomized phase II study of standard-dose versus high-dose rituximab with BEAM in autologous stem cell transplantation for relapsed aggressive B-cell non-hodgkin lymphomas: long term results.
British journal of haematologyL-PROBe: A Novel Non-anthracycline Combination Chemotherapy Regimen for Aggressive B Cell Non-Hodgkin Lymphoma in Elderly Patients.
Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood TransfusionRecent advances and future directions in mantle cell lymphoma research: report of the 2016 mantle cell lymphoma consortium workshop.
Leukemia & lymphomaUnusual multiple metastatic localisations in adult Burkitt's lymphoma. A case report.
Medical ultrasonographyClinical characteristics and survival outcome of primary effusion lymphoma: A review of 105 patients.
Hematological oncologyComplete Remission of Burkitt Lymphoma After Surgical Excision: A Case Report.
Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood TransfusionImpact of Fc gamma-receptor polymorphisms on the response to rituximab treatment in children and adolescents with mature B cell lymphoma/leukemia.
Annals of hematologyClinical association of baseline levels of conjugated dienes in low-density lipoprotein and nitric oxide with aggressive B-cell non-Hodgkin lymphoma and their relationship with immunoglobulins and Th1-to-Th2 ratio.
Journal of blood medicineMonotherapy with pixantrone in histologically confirmed relapsed or refractory aggressive B-cell non-Hodgkin lymphoma: post-hoc analyses from a phase III trial.
British journal of haematologyPixantrone-rituximab versus gemcitabine-rituximab in relapsed/refractory aggressive non-Hodgkin lymphoma.
Future oncology (London, England)Clinical Management Updates in Mantle Cell Lymphoma.
Oncology (Williston Park, N.Y.)Sporadic Burkitt's lymphoma/acute B-cell leukaemia presenting with progressive proptosis and orbital mass in a child.
The neuroradiology journalA multicenter phase II study of sepantronium bromide (YM155) plus rituximab in patients with relapsed aggressive B-cell Non-Hodgkin lymphoma.
Leukemia & lymphoma[Burkitt lymphoma, a diagnostic emergency].
La Revue du praticienMechanisms of Action and Reduced Cardiotoxicity of Pixantrone; a Topoisomerase II Targeting Agent with Cellular Selectivity for the Topoisomerase IIα Isoform.
The Journal of pharmacology and experimental therapeuticsLoss of PIM2 enhances the anti-proliferative effect of the pan-PIM kinase inhibitor AZD1208 in non-Hodgkin lymphomas.
Molecular cancerOutcomes of very elderly patients with aggressive B-cell non-Hodgkin lymphoma treated with reduced-dose chemotherapy.
International journal of clinical oncologyThe STAT3 inhibitor WP1066 synergizes with vorinostat to induce apoptosis of mantle cell lymphoma cells.
Biochemical and biophysical research communicationsAdvances and issues in mantle cell lymphoma research: report of the 2014 Mantle Cell Lymphoma Consortium Workshop.
Leukemia & lymphomaChanging patterns of chemotherapy relative dose intensity and supportive care for aggressive B-cell non-Hodgkin lymphoma.
Leukemia & lymphomaHIV associated Burkitt's lymphoma.
The Journal of the Association of Physicians of IndiaInhibition of human diffuse large B-cell lymphoma growth by JC polyomavirus-like particles delivering a suicide gene.
Journal of translational medicineHSPH1 inhibition downregulates Bcl-6 and c-Myc and hampers the growth of human aggressive B-cell non-Hodgkin lymphoma.
BloodAssociações
Organizações que acompanham esta doença — pra ter apoio e orientação
Ainda não temos associações cadastradas para Linfoma não-Hodgkin de células B agressivo.
É de uma associação que acompanha esta doença? Fale com a gente →
Comunidades
Grupos ativos de quem convive com esta doença aqui no Raras
Ainda não existe comunidade no Raras para Linfoma não-Hodgkin de células B agressivo
Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.
Tire suas dúvidas
Perguntas, dicas e experiências compartilhadas aqui na página
Participe da discussão
Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.
Fazer loginDoenças relacionadas
Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico
Referências e fontes
Bases de dados externas citadas neste artigo
Publicações científicas
Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.
- Case Report: Glofitamab in the treatment of a patient with central nervous system-involved Burkitt lymphoma.
- Clinical characteristics, treatment patterns, and survival in mantle cell lymphoma: a real-world cohort.
- Long-term follow-up demonstrates the curative potential of dual CD19/CD22 CAR-T-cell therapy alone or combined with autologous stem cell transplantation in TP53-altered relapsed/refractory B-cell non-Hodgkin lymphoma.
- Mantle Cell Lymphoma Mimicking Parotid Neoplasm: A Rare Case Report.
- Diagnostic challenges in Burkitt's lymphoma with skull base and paravertebral involvement, and hearing loss: a case report.
- Unusual Ampullary Presentation of Pediatric Burkitt Lymphoma: Case Report and Literature Review.
Bases de dados e fontes oficiais
Identificadores e referências canônicas usadas para montar este verbete.
- ORPHA:300846(Orphanet)
- MONDO:0017595(MONDO)
- GARD:21245(GARD (NIH))
- Variantes catalogadas(ClinVar)
- Busca completa no PubMed(PubMed)
- Q55787212(Wikidata)
Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.
Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar
